Combination Paclitaxel, Carboplatin and Temozolomide

New Mexico Cancer Research Alliance15 enrolled

Overview

The purpose of this study is to determine the maximum tolerable dose of temozolomide in combination with fixed dose of paclitaxel and carboplatin and to determine the overall tumor response rate with this combination and to determine the duration of response.

The objective of the research study is to test a combination of drugs to treat small cell lung cancer which has spread beyond the lungs (extensive cancer) or come back after earlier treatment (recurrent cancer).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Lung Diseases Cancer

Interventions

Combination Treatment - Cohort 1DRUG

Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1. Temozolomide at 75 mg/m2 per day from day 2 to day 6.

Combination Treatment - Cohort 2DRUG

Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1. Temozolomide at 100 mg/m2 per day from day 2 to day 6.

Combination Treatment - Cohort 3DRUG

Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1. Temozolomide at 125 mg/m2 per day from day 2 to day 6.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age greater than or equal to 18 years 2. Karnofsky performance status (KPS) of greater than or equal to 70 (Appendix B) 3. Laboratory values (performed within 14 days prior to study drug administration, inclusive). 1. Absolute neutrophil count (ANC) \>1500/mm3 2. Platelet count \>100,000/mm3 3. Hemoglobin \>10 g/dl or 100 g/l 4. BUN and serum creatinine \<1.5 times upper limit of laboratory normal 5. Total and direct bilirubin \<1.5 times upper limit of laboratory normal 6. SGOT and SGPT \<3 times upper limit of laboratory normal 7. Alkaline Phosphatase \<3 times upper limit of laboratory normal 4. A life expectancy of greater than 12 weeks 5. Subjects must give written informed consent. 6. Biopsy proven small cell lung cancer. 7. CT of chest, abdomen, pelvis and MRI of head 8. Patients with brain metastases should be asymptomatic to enter the study Exclusion Criteria: 1. No recovery from all active toxicities of prior therapies. 2. Subjects who are poor medical risks because of non-malignant systemic disease as well as those with acute infection treated with intravenous antibiotics. 3. Frequent vomiting or medical condition that could interfere with oral medication intake (eg, partial bowel obstruction). 4. Concurrent malignancies at other sites with the exception of surgically cured carcinoma in-site of the cervix and basal or squamous cell carcinoma of the skin. Prior malignancies which have not required anti-tumor treatment within the preceding 24 months are eligible. 5. Known HIV positivity or AIDS-related illness. 6. Pregnant or nursing women. 7. Women of childbearing potential who are not using an effective method of contraception. Women of childbearing potential must have a negative serum pregnancy test 24 hours prior to administration of study drug and be practicing medically approved contraceptive precautions. 8. Men who are not advised to use an effective method of contraception. 9. Progression of disease on prior chemotherapy with paclitaxel and carboplatin, either as single agent or in combination. 10. Known hypersensitivity reaction to taxoid or platinum compound.

Locations (1)

University of New Mexico Cancer Center

Albuquerque, New Mexico, United States

Outcomes

Primary Outcomes

Maximum Tolerated Dose of Temozolomide in Combination with Fixed Doses of Paclitaxel and Carboplatin

Temozolomide was administered at different dose levels (see Cohorts 1-4) until the maximum tolerated dose (MTD) was reached. MTD is the dose at which 0/6 or 1/6 patients in the cohort experience dose limiting toxicity (DLT) during the first 4 week cycle with the next higher dose having at least 2/3 or 2/6 patients experiencing DLT. DLT will have occurred when the patient has 1 or more Grade 4 hematologic or nonhematologic toxicities. A DLT must occur in the first cycle of the combination and must be at least possibly attributed to the treatment regimen. Toxicities will be graded according to the NCI CTCAE Version 3.0.

Time frame: 4 months

Secondary Outcomes

Tumor response rate

Tumor response is evaluated according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.0 as determined by the investigator. Complete response (CR): Disappearance of all evidence of target and non-target lesions. Partial response (P): \>= 30% reduction from baseline in the sum of the longest diameter of all lesions. CR and PR criteria should be met again after 4 weeks and before 6 weeks after initial assessment. Stable Disease (SD): Neither sufficient increase to qualify for PD nor sufficient shrinkage to qualify for PR. Progressive disease (PD) for target lesions: \>= 20% increase in the sum of diameters of the target lesions taking as reference the smallest sum on study, and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered . PD for non-target lesions is defined as unequivocal appearance of one or more new malignant lesions or unequivocal progression of existing non-target lesions.

Time frame: 7 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.